A case of successful concurrent anti-cancer treatment in a patient who developed follicular lymphoma during treatment with afatinib for advanced lung adenocarcinoma

Kentaro Masuhiro; Genju Koh; So Takata; Shingo Nasu; Hiromune Takada; Satomu Morita; Ayako Tanaka; Takayuki Shiroyama; Naoko Morishita; Hidekazu Suzuki; Norio Okamoto; Hiromi Kawasumi; Chihiro Konishi; Tomonori Hirashima

Respiratory Medicine Case Reports (Jan 2019)

A case of successful concurrent anti-cancer treatment in a patient who developed follicular lymphoma during treatment with afatinib for advanced lung adenocarcinoma

Kentaro Masuhiro,
Genju Koh,
So Takata,
Shingo Nasu,
Hiromune Takada,
Satomu Morita,
Ayako Tanaka,
Takayuki Shiroyama,
Naoko Morishita,
Hidekazu Suzuki,
Norio Okamoto,
Hiromi Kawasumi,
Chihiro Konishi,
Tomonori Hirashima

Affiliations

Kentaro Masuhiro: Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan
Genju Koh: Department of Oncology, Yao Tokushukai General Hospital, Osaka, Japan
So Takata: Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan
Shingo Nasu: Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan
Hiromune Takada: Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan
Satomu Morita: Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan
Ayako Tanaka: Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan
Takayuki Shiroyama: Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan
Naoko Morishita: Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan
Hidekazu Suzuki: Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan
Norio Okamoto: Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan
Hiromi Kawasumi: Department of Clinical Laboratory, Osaka Habikino Medical Center, Osaka, Japan
Chihiro Konishi: Department of Pharmacy, Yao Tokushukai General Hospital, Osaka, Japan
Tomonori Hirashima: Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan; Corresponding author. Department of Thoracic Oncology, Osaka Habikino Medical Center, Address: 3-7-1, Habikino, Habikino city, Osaka, 583-8588, Japan. Tel.: +81 72 957 2121; fax: +81 72 957 8002.

Journal volume & issue: Vol. 28

Abstract

Read online

The present report describes the case of a 64-year-old woman with advanced lung adenocarcinoma expressing mutant epidermal growth factor receptor (EGFR). The patient developed follicular lymphoma during treatment with the EGFR-tyrosine kinase inhibitor afatinib. Standard immunochemotherapy for follicular lymphoma was introduced in addition to continuing treatment with afatinib for lung cancer. Immunochemotherapy was effective and improved the patient's performance status while afatinib controlled the progression of lung cancer. Our case study suggests that it is safe to introduce standard immunochemotherapy for patients who develop malignant lymphoma while continuing treatment with tyrosine kinase inhibitors for lung adenocarcinoma expressing mutant EGFR. Keywords: Lung cancer, Follicular lymphoma, Afatinib, Synchronous, Metachronous, Double primary malignant tumors

Published in Respiratory Medicine Case Reports

ISSN: 2213-0071 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the respiratory system
Website: http://www.journals.elsevier.com/respiratory-medicine-case-reports/

About the journal